BRCA1 and ovarian cancer: A genotype-directed clinical trial is currently ongoing at our institution and other academic centers to determine the efficacy of PARP inhibition in somatic cfDNA BRCA1/2-mutant metastatic breast cancer [11], and the results of this trial may help expand the population of patients who benefit from PARP inhibitors, similar to what has been observed in ovarian cancer.